Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP

Investigational New Drugs

Volumn 23, Issue 4, 2005, Pages 287-297

  Kosmider, Beata ^a   Wojcik, Izabela ^b   Osiecka, Regina ^a   Bartkowiak, Jacek ^b   Zyner, Elzbieta ^b   Ochocki, Justyn ^b   Liberski, Pawel ^b  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

A549 cells; Apoptosis; cis DDP; cis Pt(II) complex of 3 aminoflavone; Necrosis

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ACRIDINE ORANGE; BIS(3 AMINOFLAVONE)DICHLOROPLATINUM; CISPLATIN; ETHIDIUM BROMIDE; PLATINUM DERIVATIVE; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL DEATH; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SCREENING; DRUG USE; GENE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; STAINING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; GENE EXPRESSION REGULATION; HUMANS; ORGANOPLATINUM COMPOUNDS; RNA, MESSENGER; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 17644408961     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-1437-z     Document Type: Article

References (44)

1. Dancey J, Le Chevalier T: Non-small cell lung cancer: An overview of current management. Eur J Cancer 33: S2-S7, 1997
2. Borner MM, Joncourt F, Hotz MA: Similarity of apoptosis induction by 2-chlorodeoxyadenosine and cisplatin in human mononuclear blood cells. Br J Cancer 76: 1448-1454, 1997
3. Siemer S, Ømskov D, Guerra B, Boldyreff B, Issinger O-G: Determination of mRNA, and protein levels of p53, MDM2 and protein kinase CK2 subunits in F9 cells after treatment with the apoptosis-inducing drugs cisplatin and carboplatin. Int J Biochem & Cell Biol 31: 661-670, 1999
4. Pestell KE, Hobbs SM, Titley JC, Kelland LR, Walton MI: Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol 57: 503-511, 2000
5. Choi JH, Ahn KS, Kim J, Hong YS: Enhanced induction of Bax gene expression in H460 and H1299 cells with the combined treatment of cisplatin and adenovirus mediated wt-p53 gene transfer. Exp Mol Medicine 32: 23-28, 2000
6. Hagopian GS, Mills GB, Khokhar AR, Bast Jr. RC, Siddik ZH: Expression of p53 in Cisplatin-resistant Ovarian Cancer Cell Lines: Modulation with the novel Platinum Analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)- platinum(IV). Cancer Res 5: 655-663, 1999
7. Prokop A, Wieder T, Sturm I, Essmann E, Seeger K, Wuchter C, Ludwig W-D, Henze G, Dörken B, Daniel PT: Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 14: 1606-1613, 2000
8. Kawakami K, Tsukuda M, Mizuno H, Nishimura G, Ishii A, Hamajima K: Alteration of the Bcl-2/Bax Status of Head and Neck Cancer Cell Lines by Chemotherapeutic Agents. Anticancer Research 19: 3927-3932, 1999
9. Fan J, Bertino JR: Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair. Mol Pharmacol 56: 966-972, 1999
10. Edelman M, Quam H, Mullins B: Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines. Cancer Chemother Pharmacol 48: 141-144, 2001
11. Nijveldt RJ, Nood E, Hoorn DEC, Boelens PG, Norren K, Leeuwen PAM: Flavonoids: A review of probable mechanisms of action and potential applications. Am J Clin Nutr 74: 418-425, 2001
12. Zyner E, Erxleben A, Ochocki J, Lippert B: Cu(II) complex of 3-aminoflavone. VII International Symposium on Inorganic Biochemistry 51, 2001
13. Zyner E, Graczyk J, Ochocki J: Pt(II) and Pd(II) complexes of 3-aminoflavone: In vitro and in vivo evaluation. Pharmazie 54: 945-946, 1999
14. Ochocki J, Zyner E. Patent Nr P.185585, 2003
15. Lieberthal W, Triaca V, Levine J: Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: Apoptosis vs. necrosis. Am Physiol Soc 3: F700-08, 1996
16. Leite M, Quinta-Costa M, Leite PS, Guimarães JS: Critical evaluation of techniques to detect and measure cell death - studey in a model of UV radiation of the leukaemic cell line HL60. Anal Cell Pathol 19: 139-151, 1999
17. Vermes I, Haanen C, Reutelingsperger C: Flow cytometry of apoptotic cell death. J Immunol Methods 243: 167-190, 2000
18. Elstein KH, Zucker RM: Comparison of cellular and nuclear flow cytometric techniques for discriminating apoptotic subpopulations. Exp Cell Res 211: 322-331, 1994
19. Gasiorowski K, Brokos B, Kulma A, Ogorzalek A, Skorkowska K: A comparison of the methods applied to detect apoptosis in genotoxically-damaged lymphocytes cultured in the presence of four antimutagens. Cell Mol Biol Let 6: 141-159, 2001
20. Anan K, Morisaki T, Katano M, Ikubo A, Tsukahara Y, Kojima M, Uchiyama A, Kuroki S, Torisu M, Tanaka M: Assessment of c-erbB2 and vascular endothehal growth factor mRNA expression in fine-needle aspirates from early breast carcinomas: Preoperative determination of malignant potential. Eur J Surg Oncol 24: 28-33, 1998
21. Schottelius A, Brennscheidt U, Ludwig W-D, Mertelsmann RH, Herrmann F, Lübbert M: Mechanisms of p53 alteration in acute leukemias. Leukemia 8: 1673-1681, 1994
22. Mori S, Murakami-Mori K, Jewett A, Nakamura S, Bonavida B: Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis. Cancer Res 56: 1874-1879, 1996
23. Wang T, Phang T: Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55: 2487-2489, 1995
24. Bueso-Ramos C-E, Yang Y, DeLeon E, McCown P, Stass SA, Albitar M: The human MDM-2 oncogene is overexpressed in leukemias Blood 82: 2617-2623, 1993
25. Strobel T, Swanson L, Korsmeyer S, Cannistra SA: BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci 93: 14094-14099, 1996
26. Lam V, McPherson JP, Salmena L, Lees J, Chu W, Sexsmith E, Hedley DW, Freedman MH, Reed JC, Malkin D, Goldenberg GJ: p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leukemia Res 23: 871-880, 1999
27. Tsurata Y, Mandai M, Konishi I, Kuroda H, Kusakari T, Yyra Y, Hamid AA, Tamura I, Kariya M, Fujii S: Combination effect of adenovirus-mediated pro-apoptotic box gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines. Eur J Cancer 37: 531-541, 2001
28. Lee RH, Song JM, Park MY, Kang SK, Kim UK, Jung JS: Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochem Pharmacol 62: 1013-1023, 2001
29. Racz I, Tory K, Gallyas F, Berente Z, Osz E, Jaszlits L, Bernath S, Sumegi B, Rabloczky G, Literati-Nagy P: BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephotoxicity of cisplatin without compromising its antitumor activity. Biochem Pharmacol 63: 1099-1011, 2002
30. Kelland LR: Preclinical perspectives on platinum resistance. Drugs 59: 1-8, 2000
31. Reedijk J: Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell? Chem Rev 99: 2499-2510, 1999
32. Zhang K, Chew M, Yang EB, Wong KP, Mack P: Modulation of cisplatin cytotoxicty and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms. Mol Pharmacol 59: 837-843, 2001
33. Lippert B: Cisplatin: Chemistry and Biochemistry of a leading anticancer drug. Zürich, Verlag, Helv. Chim. Acta., Wiley-VCH, Weinheim, 1999
34. Järvinen K, Pietarinen-Runtti P, Linnainmaa K, Raivio KO, Krejsa CM, Kavanagh T, Kinnula VL: Antioxidant defense mechanisms of human mesothelioma and lung adenocarcinoma cells. Am J Physiol Lung Cell Mol Physiol 278: L696-L702, 2000
35. Kosmider B,Zyner E, Osiecka R, Ochocki J: Genotoxicity of cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP in A549 cells evaluated by the comet assay. Can J Physiol Pharmacol 82: 353-8, 2004
36. Kosmider B, Osiecka R, Zyner E, Ochocki J: Comparison between the genotoxicity of cis-Pt(II) complex of 3-aminoflavone and cis-DDP in lymphocytes evaluated by the comet assay. Drug Chem Toxicol 28: 231-244, 2005
37. Ciesielska E, Studzian K, Zyner E, Ochocki J, Szmigiero L: DNA damage and apoptosis induction in L1210 cells by cis-diamminedichloroplatinum (II) and its new aminoflavone analogue. Cell Mol Biol Let 5: 441-450, 2000
38. Bai F, Matsui T, Ohtani-Fujita N, Matsukawa Y, Ding Y, Sakai T: Promoter activation and following induction of the p21/WAF1 gene by flavone is involved in G1 phase arrest in A549 lung adenocarcinoma cells. FEBS Letters 437: 61-64, 1998
39. Priya SD, Devi CSS: Protective effect of quercetin in cisplatin-induced cell injury in the rat kidney. Indian J Pharmacol 31: 422-426, 1999
40. Weijl NI, Clenton FJ, Osanto S: Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treatment Reviews 23: 209-240, 1997
41. Kosmider B, Wyszynska K, Janik-Spiechowicz E, Osiecka R, Zyner E, Ochocki J, Ciesielska E, Wasowicz W: Evaluation of the genotoxicity of cis-bis(3-aminoflavone)dichloroplatinum(II) in comparison with cis-DDP. Mutat Res 558: 93-110, 2004
42. Kosmider B, Osiecka R, Ciesielska E, Szmigiero L, Zyner E, Ochocki J: Induction of apoptosis and necrosis in lymphocytes by the cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP. Mutat Res 558: 169-179, 2004
43. Kosmider B, Zyner E, Osiecka R, Ochocki J: Induction of apoptosis and necrosis in A549 cells by the cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP. Mutat Res 563: 61-70, 2004
44. Kosmider B, Osiecka R: Flavonoid compounds: A review of anticancer properties and interactions with cis-diamminedichloroplatinum(II). Drug Develop Res 63: 200-211, 2004